OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.55 Million Position in InflaRx (NASDAQ:IFRX)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in InflaRx (NASDAQ:IFRX - Free Report) by 21.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 625,589 shares of the company's stock after selling 172,287 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.06% of InflaRx worth $1,545,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Two Sigma Securities LLC bought a new position in InflaRx during the 4th quarter worth about $28,000. Walleye Capital LLC purchased a new position in InflaRx during the 4th quarter worth approximately $51,000. Cubist Systematic Strategies LLC purchased a new stake in InflaRx during the fourth quarter worth $55,000. Geode Capital Management LLC grew its position in InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after buying an additional 11,900 shares during the period. Finally, Commonwealth Equity Services LLC grew its position in InflaRx by 20.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock valued at $275,000 after buying an additional 19,000 shares during the period. Hedge funds and other institutional investors own 42.39% of the company's stock.

InflaRx Stock Performance

Shares of NASDAQ:IFRX traded up $0.08 during trading hours on Monday, reaching $1.74. The stock had a trading volume of 42,644 shares, compared to its average volume of 230,453. The firm's 50 day moving average is $1.28 and its 200-day moving average is $1.83. The stock has a market capitalization of $116.48 million, a price-to-earnings ratio of -1.61 and a beta of 1.57. InflaRx has a 1 year low of $0.82 and a 1 year high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. The company had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.03 million. Analysts forecast that InflaRx will post -1.04 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on IFRX shares. Oppenheimer started coverage on shares of InflaRx in a research report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target for the company. Guggenheim lifted their target price on shares of InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 26th. HC Wainwright restated a "buy" rating and set a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st. Finally, Cantor Fitzgerald started coverage on shares of InflaRx in a research report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price target on the stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.